Home › Multiple Myeloma › District of Columbia › Washington
Pag-aaral pangklinika para sa Multiple Myeloma sa Washington, DC
Isang pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Washington. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Nagre-recruitPhase 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Nagre-recruitPhase 3
- Research Site, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Nagre-recruitObservasyonal na pag-aaral
- National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Nagre-recruitPhase 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
Tissue Collection for Studies of Lymph Cancer
Nagre-recruitObservasyonal na pag-aaral
- National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Nagre-recruitPhase 4
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi ang layo
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Nagre-recruitPhase 3
- Center for Cancer and Blood Disorders, Bethesda · 7 mi ang layo
18F-Fluciclovine PET/CT in Multiple Myeloma
Nagre-recruitPhase 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Nagre-recruitPhase 3
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi ang layo
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Nagre-recruitPhase 2
- Lombardi Comprehensive Cancer Center, Washington D.C.
Collection of Tissue Samples for Cancer Research
Nagre-recruitObservasyonal na pag-aaral
- National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Nagre-recruitPhase 3
- Georgetown University Medical Center, Washington D.C.
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Nagre-recruitPhase 3
- MedStar Washington Hospital Center MedStar Georgetown Cancer Institute, Washington D.C.
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Nagre-recruitPhase 2
- GSK Investigational Site, Bethesda · 7 mi ang layo
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Nagre-recruitPhase 3
- Sibley Memorial Hospital, Washington D.C.
Mosaic Trial for Stem Cell Transplant Recipients
Nagre-recruit
- Georgetown University School of Medicine, Washington D.C.
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Maryland Oncology Hematology - Silver Spring /ID# 268562, Silver Spring · 7 mi ang layo
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Nagre-recruitPhase 1/2
- The Center for Cancer and Blood Disorders (CCBD), Bethesda · 7 mi ang layo
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Nagre-recruitPhase 3
- Sibley Memorial Hospital, Washington D.C.
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Cancer Support Community Research & Training Institute, Washington D.C.
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Nagre-recruitPhase 3
- GSK Investigational Site, Washington D.C.
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Nagre-recruitPhase 1/2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Pag-aaral para sa Multiple Myeloma sa ibang lungsod
- New York City, NY60 pag-aaral
- Boston, MA42 pag-aaral
- Atlanta, GA42 pag-aaral
- Houston, TX38 pag-aaral
- Durham, NC37 pag-aaral
- Nashville, TN32 pag-aaral
- Denver, CO27 pag-aaral
- St. Louis, MO24 pag-aaral
- Rochester, MN24 pag-aaral
- Columbus, OH24 pag-aaral
- Baldwin Park, CA23 pag-aaral
- Edison, NJ22 pag-aaral
Iba pang pag-aaral sa Washington
- Kanser (lahat ng uri)58 pag-aaral
- Non-Small Cell Lung Cancer55 pag-aaral
- Kanser sa Suso46 pag-aaral
- Metastatic Cancer43 pag-aaral
- Kanser sa Baga41 pag-aaral
- Kanser sa Prostate38 pag-aaral
- Obesity33 pag-aaral
- Colorectal Cancer29 pag-aaral
- Sakit sa Puso at Ugat ng Dugo28 pag-aaral
- Kanser sa Pantog26 pag-aaral
- Acute Myeloid Leukemia24 pag-aaral
- Kanser sa Ovary23 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.